KR100967813B1 - A composition comprising the extract of Raphani semen as an active ingredient showing anti-obesity and anti-hyperlipidemia activity - Google Patents

Abstract

The invention of the moth ( Raphani semen ) relates to a composition for the prevention and treatment of hyperlipidemia or obesity containing the extract as an active ingredient, in detail the moth extract extract of the present invention in vivo ( in In vivo ) significantly reduced the body weight, the weight of the fat around the ovary, the blood lipid content, blood leptin and adiponectin content in the high-fat diet, the composition is a pharmaceutical composition for the prevention and treatment of hyperlipidemia or obesity or It can be usefully used as a dietary supplement.

Moxa, hyperlipidemia, obesity

Description

A composition comprising the extract of Raphani semen as an active ingredient showing anti-obesity and anti-hyperlipidemia activity}

The present invention relates to a pharmaceutical composition or health functional food for the prevention and treatment of hyperlipidemia or obesity containing the extract of Nakbokja as an active ingredient.

Schoen FJ et al . , Robbins pathologic basis of disease, 5th ed., Pp. 473-484, 1994

[Ref. 2] Kook Seung-rae et al., Journal of Family Medicine, 18 (3) , pp.317-327, 1997

Document 3 Kunitomi M, et al . , Int . J. Obes . Relat . Metab . Disord . , 26 , pp.361-9, 2002

[4] Mitchell M, et al . , Reproduction , 130 , pp.583-97, 2005

[Reference 5] Chinese Medicine Dictionary, Chang Min Kim, pp.715-718, 1997

Document 6 Sahai A, et al . , Am . J. Physiol . Gastrointest . Liver Physiol . , 287 , pp.G1035-43, 2004

Hyperlipidemia is a condition in which lipid components in the blood are increased more than usual. The major components of serum lipids are composed of fat-soluble substances such as cholesterol, triglycerides, phospholipids, and free fatty acids, and depending on which of these lipids increases, hypercholesterinemia, hypertriglyceridemia, etc. It is called. Increased serum cholesterol and triglycerides are the most common causes of hyperlipidemia. Accumulation of excess fat causes blood circulation disorders and microcirculation failure, resulting in atherosclerosis, ischemic heart disease, cerebral infarction, hypertension, obesity and diabetes. May result (Schoen FJ et al . , Robbins pathologic basis of disease, 5th ed., Pp. 473-484, 1994).

Cholesterol is produced mainly in the liver and is present in the blood in the form of small round particles called lipoproteins, which carry cholesterol throughout the body. There are two types of lipoproteins, low density lipoprotein (LDL) and high density lipoprotein (HDL), and because high density lipoproteins carry cholesterol from other tissues to the liver, a lot of high-density lipoprotein removes cholesterol from blood vessels. On the other hand, low-density lipoproteins are mainly produced by the liver and transport cholesterol to other tissues of the human body, so a lot of low-density lipoproteins accumulate a lot of cholesterol in blood vessels to promote arteriosclerosis, and about 70% of blood cholesterol is present as low-density lipoproteins, which are bad cholesterol.

In fact, cholesterol is an essential ingredient for normal functioning of the human body, a nutrient necessary for making cells, and a component of various hormones such as corticosteroids, male hormones, and female hormones. do. In addition, cholesterol is a nutrient necessary for the human body, such as being a component of a biological membrane and being shot as a starting material for hormonal synthesis. However, excessive cholesterol intake is known to accumulate in the blood vessels and cause heart disease, and there is no preventive method except low-cholesterol diet, and taking drugs such as cholesterol-lowering drugs is effective. Use is extremely limited due to reasons such as causing side effects such as liver dysfunction.

Hyperlipidemia is a condition that is high in blood cholesterol or triglycerides with yellow nodules on the back of the hand and nodules around the ankles and wrists. Nodules develop on the eyelids and white rings appear around the iris. Since the 1980s, hyperlipidemia has increased due to overeating, animal fat intake, lack of exercise, smoking, heavy drinking and stress.

Hyperlipidemia drugs are used to lower levels of excess blood fat, especially cholesterol and triglycerides. Major drugs used in lipid metabolism include statins, bile acid blockers, and fibric acid derivatives. These drugs act by different mechanisms. The choice of therapeutic agents for hyperlipidemia may be a combination of these drugs, depending on the type of lipoproteins that have been increased, and they require long-term oral daily use. These drugs effectively lower cholesterol and blood levels, but have the disadvantage of having side effects. Statins can cause nausea, headache, abdominal pain and diarrhea or constipation, which can cause muscle inflammation, and bile acid blockers can reduce the intestinal absorption of vitamins A, D, and K. And fibric acid derivatives are unsuitable drugs for kidney disease, liver disease or gallbladder disease. Therefore, there is a growing demand for the development of medicines and functional foods containing natural products in place of these preparations (Kook Seung-rae et al., Journal of Family Medicine, 18 (3) , pp.317-327, 1997).

Obesity is regarded as obesity when the body fat is excessively accumulated and the body weight exceeds at least 20% more than the maximum value of the healthy weight calculated according to the height. Obesity puts pressure on organs and joints, causing a number of health problems, including back pain, hip and knee pain, and shortness of breath, and potentially fatalities such as coronary artery disease, stroke, and high blood pressure. It increases the risk of illnesses and brings psychological problems such as depression. Obesity also increases the risk of various chronic diseases. Obese people have high blood cholesterol levels, which increases the risk of atherosclerosis, which accumulates fat in the lining of the arteries, which causes high blood pressure and coronary artery disease. Arterial thrombosis and embolism in which blood vessels are clogged by blood clots often appear, and the risk of cholelithiasis is greater, and diabetes tends to be more likely. Several cancers, such as breast and uterine cancers, are also more common in obese people. Excessive weight compresses joints, especially osteoarthritis of the hips and knees is common in obese people. Sleep apnea as a respiratory disease is also associated with obese people. The most common criterion for determining obesity is now known as the amount and distribution of abdominal fat (Kunitomi M, et. al . , Int . J. Obes . Relat . Metab . Disord . , 26 , pp. 361-9, 2002).

Obesity patients are increasing all over the world, and efforts are being made to determine the cause of obesity. As a result of these efforts, it is known that the cause of obesity is caused by abnormality of energy homeostasis due to the reduction of exercise. As a treatment, diet and exercise are essential, and appetite suppressants can be used, but due to side effects, it is rarely recommended. Therefore, in the case of therapeutics using natural extracts, which have been used for a long time and have been proved to be harmless to humans, resistance or safety problems caused by existing therapeutics can be overcome (Mitchell M, et. al . , Reproduction , 130 , pp.583-97, 2005).

Leptin (leptin) is known as appetite control hormone, it has been found to play a variety of roles in addition. It is known that as fat accumulation increases in ob / ob mice, blood levels of leptin increase, and the body of obese patients becomes resistant to leptin.

Adipose tissue was recognized as not necessary until the late 1990s, but the discovery of adiponectin, which plays a key role in energy metabolism and obesity, has raised awareness of the importance of adipose tissue. Increased fat accumulation decreases adiponectin secretion and is a good indicator of increased risk of developing diabetes, heart disease, and cancer. In addition, since adiponectin is circulated in a large amount of plasma, it has been used as an indicator to test for fat metabolism abnormalities, and there is a research report that acts as an inflammation inhibitor. Therefore, many studies on adiponectin and leptin related to obesity have been conducted.

The Locust is a plant belonging to the Cruciferaceae radish ( Raphanus sativus L. ) is the seed of a woman. Dried seeds are oval or round ovate, slightly flat, about 3 mm long and 2.5 mm wide. The surface is reddish brown with several longitudinal grooves on one side and a seed on one end. The underside is brown and raised in round dots. When viewed with a magnifying glass, there is a tight net pattern throughout the seeds. The vagina is hard and split into yellowish white or yellowish kernels, and the kernels have essential oils. When the seeds grow in summer and autumn, they give up the seeds and dry them in the sun, then remove the seeds by hand, remove the miscellaneous goods, dry them in the sun, and use them as herbal medicines (Chinese medicine dictionary, Kim Chang-min, pp.715, 1997).

The moths contain antibacterial substances, which have distinct inhibitory effects against Staphylococcus aureus and Escherichia coli, and have pharmacological effects such as concentricity and ringworm fungus against skin fungi. It is effective in treating the symptoms of rising sun, decreasing breathing, helping digestion, and cutting out phlegm, and bronchial asthma caused by sea water, food gas, chest swelling and bloating, and dysentery due to dysentery. Nabokja is prescribed for the treatment (Chinese medicine dictionary, Kim Chang-min et al., Pp.716-718, 1997). Recently, moth extracts or some components have been reported to exhibit potent antimutagenic activity, antibacterial, antihypertensive and anti-inflammatory effects, but no studies on antihyperlipidemia or anti-obesity effects have been conducted.

Therefore, the present inventors significantly increased the weight, weight of ovarian fat, blood lipid content, blood leptin and adiponectin content through animal experiments in which high-fat feed was taken using the extract of nabokgi water from the natural ingredients that have been used as herbal medicine. To reduce the antihyperlipidemia or anti-obesity effect was completed the present invention.

In order to achieve the above object, the present invention provides a pharmaceutical composition for the prevention and treatment of hyperlipidemia or obesity, containing the extract of Nakbokja as an active ingredient.

In addition, the present invention provides a health functional food for the prevention and improvement of hyperlipidemia or obesity containing the extract of Nakbokja as an active ingredient.

The moths, as defined herein, are radish ( Raphanus) sativus L.), gaetmu (Raphanus sativus var. hortensis for. raphanistroides Makino) , or non-Western Buttercup (Raphanus raphanistrum L. ), preferably radish ( Raphanus sativus L. ), dried seeds.

Extracts as defined herein include water, including purified water, lower alcohols having 1 to 4 carbon atoms or solvents selected from mixed solvents thereof, preferably extracts soluble in water.

Hereinafter, the present invention will be described in detail.

The moth extract of the present invention can be prepared as follows. The dried moth is a solvent selected from water including purified water, a lower alcohol having 1 to 4 carbon atoms or a mixed solvent thereof, preferably water, 0 to 120 ° C, preferably 100 to 100 minutes to 1 day, preferably Extracting for 150 minutes; Through the manufacturing method comprising the second step of filtration concentration and freeze-drying it can be obtained the extract of the present invention.

The present invention provides a pharmaceutical composition for the prevention and treatment of hyperlipidemia or obesity, which contains the extract of the moths obtained by the above method as an active ingredient.

In another aspect, the present invention provides a health functional food for the prevention and improvement of hyperlipidemia or obesity, containing the extract of the Nakbokja obtained by the above production method as an active ingredient.

The pharmaceutical composition for the prevention and treatment of hyperlipidemia or obesity containing the moth extract of the present invention comprises 0.1 to 50% by weight based on the total weight of the composition.

The pharmaceutical composition containing the extract of Nakbokgi of the present invention may further include suitable carriers, excipients and diluents commonly used in the preparation of pharmaceutical compositions.

The pharmaceutical composition containing the extract of Nakbokjagi of the present invention may be prepared in the form of powder, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, oral formulations, external preparations, suppositories, and sterile injectable solutions according to conventional methods. Can be formulated and used. Carriers, excipients and diluents which may be contained in the composition containing the compound include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium Silicates, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents and surfactants are usually used. Solid form preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, which include at least one excipient such as starch, calcium carbonate, sucrose ( It is prepared by mixing sucrose or lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.

The amount of the extracts of the present invention may vary depending on the age, sex, and weight of the patient, but 0.1 to 100 mg / kg may be administered once to several times daily. The dosage may also be increased or decreased depending on the route of administration, the severity of the disease, sex, weight, age, and the like. Therefore, the above dosage does not limit the scope of the present invention in any aspect.

The pharmaceutical composition may be administered to various mammals such as mice, mice, livestock, humans, and the like. All modes of administration can be expected, for example by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebroventricular injection.

The present invention provides a dietary supplement for the prevention and improvement of hyperlipidemia or obesity, including the extract of Nakbokja as an active ingredient. Foods to which it may be added include various foods, powders, granules, tablets, capsules, syrups, beverages, gums, teas, vitamin complexes, and health functional foods.

It may also be added to foods or beverages for the purpose of preventing hyperlipidemia or obesity. At this time, the amount of the extract from the Nakbokja in the food or beverage may be added to 0.01 to 15% by weight of the total food weight, the health functional beverage composition may be added in a ratio of 0.02 to 5 g, preferably 0.3 to 1 g based on 100 ml. .

The health functional beverage composition of the present invention is not particularly limited to other ingredients except for containing the extract as an essential ingredient in the indicated ratio, and may contain various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks. . Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And sugars such as conventional sugars such as polysaccharides such as dextrin, cyclodextrin and the like and xylitol, sorbitol, erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (tautin, stevia extract) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of such natural carbohydrates is generally about 1 to 20 g, preferably about 5 to 12 g per 100 ml of the composition of the present invention.

In addition to the above, the extract of the present invention is a variety of nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, such as flavoring agents, coloring and neutralizing agents (such as cheese, chocolate), pectic acid and salts thereof, alginic acid and its Salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. In addition, the extract of the present invention may contain a pulp for the production of natural fruit juices and vegetable drinks. These components can be used independently or in combination. The proportion of such additives is not so critical but is usually selected in the range of 0 to about 20 parts by weight per 100 parts by weight of the extract of the present invention.

As described above, in the present invention, the extract of Nabokjab was administered orally through high-fat feed mice, effectively inhibiting blood total cholesterol, triglycerides, low density lipoprotein, blood leptin and adiponectin, and the high density lipoprotein content. By increasing the anti-hyperlipidemia and anti-obesity effect has been confirmed that by using it can be useful as a pharmaceutical composition or health functional food with a hyperlipidemia and obesity inhibitory effect.

Hereinafter, the present invention will be described in detail. However, the following Examples, Reference Examples and Experimental Examples are merely illustrative of the present invention, but the content of the present invention is not limited thereto.

Example  One. Mob  Preparation of Water Extract

Nabok was purchased from Daewon Pharmaceutical Co., Ltd. (Daegu, Korea), washed with water and used after drying. 200 g of dry weight of moth was taken, and hot water was poured into 1.3 L purified water at 100 ° C. for 150 minutes, and then concentrated by filtration to obtain a sample of the present invention (hereinafter referred to as “RS”) by lyophilization (final yield 12.09%). It was used for the following experiment.

Example  2. Mob  Preparation of Methanol Extracts

Nabok was purchased from Daewon Pharmaceutical Co., Ltd. (Daegu, Korea), washed with water and used after drying. Take 200 g of dry weight of moths, soak in 1.2 L methanol, leave at room temperature for 5 days, and concentrate under reduced pressure to obtain a sample of the present invention (hereinafter referred to as “RS-M”) (final yield 6.78%) It was used for the experiment.

Reference Example  1. Experimental animals and Experimental  Ready

120 adult female ICR mice (SLC, Japan) were used after 7 days of acclimatization in the laboratory environment. AIN-76A containing 40% beef tallow based on body weight after feeding the high fat diet of Table 1 for 6 days. About half of the animals showing similar adaptability to the high fat diet (Dyets, PA, USA) were selected and used in the following experiments. In the normal feed control group, the normal feed of Table 1 was supplied during the experiment period, and the high fat feed was continuously supplied for 84 days from 6 days before the start of drug administration. Metformin, used as a reference drug, is an oral hypoglycemic agent and is currently one of the most widely used comparative drugs in the search for the efficacy of candidates for treating metabolic syndrome including obesity.Wako Chemicals, Osaka, Japan Purchased.

As shown in Table 2 below, 10 experimental animals were used per group, and metformin 250 mg / kg administration group and the doses of RS 125, 250 and 500 mg / kg obtained in Example 1 were 84 Each was administered orally for days.

Normal feed
(g / kg diet) High fat feed
(g / kg diet) Ingredient Casein 200 200 DL-Methionine 3 3 Corn starch 150 150 Sucrose 500 150 Cellulose 50 0 Corn oil 50 0 Beef tallow 0 400 Mineral mixture 35 35 Vitamin mixture 10 10 Choline bitartrate 2 2 Energy (kJ / g) 0.91 1.30 Protein (% kcal / kg) 13.3 13.3 Carbohydrate (% kcal / kg) 47.4 19.8 Fat (% kcal / kg) 8.0 65.7 Fiber (% kcal / kg) 8.0 0 Other 23.3 1.3

Experimental group Dosage The number of animals menstruum term Normal diet Normal feed
Control vehicle only 10 horses Purified water
(10 ml / kg) High fat feed will continue to be supplied for 84 days starting 6 days prior to the start of drug administration. AIN-76A high fat feed with 40% beef tallow High Fat Feed Control vehicle only Metaformin
Administration group 250 mg / kg RS administration group 125 mg / kg 250 mg / kg 500 mg / kg

Experimental Example  1. Morphological Change

Experimental animal body weight of Reference Example 1 is administered on day 7, 7, 21, 35, 49, 63, 77, 83 and the experimental results as shown in Table 3 and Figure 1A, body weight change is a high fat feed day 7 days all high fat feed day Afterwards, body weight was significantly increased compared to metformin, RS 500 and 250 mg / kg control group.

Experimental group
weight Weight gain (g)
Medication start date 84 days of administration Control Normal feed 27.86 ± 0.94 37.42 ± 2.48 9.56 ± 2.44 High fat feed 33.15 ± 2.03 * 55.99 ± 3.79 * 22.84 ± 3.08 * Metaformin 250 mg / kg 33.01 ± 2.24 * 44.22 ± 2.09 *, # 11.21 ± 2.19 # RS administration group 500 mg / kg 33.27 ± 2.74 * 41.98 ± 1.92 *, # 8.71 ± 2.84 # 250 mg / kg 33.00 ± 2.13 * 43.83 ± 2.94 *, # 10.83 ± 2.66 # 125 mg / kg 33.00 ± 2.47 * 50.58 ± 1.96 *, # 17.58 ± 2.78 *, # Statistical significance compared to normal feed * p <0.01;
Statistical significance # p <0.01 compared to high fat diet

1-2. Ovarian fat mass measurement

On the final sacrificial day of the experimental animal of Reference Example 1 was isolated the fat around the ovary and then measured the wet weight (g), fat weight per body weight was calculated in order to reduce the change in fat weight according to the weight.

As a result, as shown in Table 4, a significant increase in fat weight was recognized in the high fat feed control group as compared to the normal control group, but it was confirmed that the significant ovarian fat weight decreased in all the administration groups as compared to the high fat feed control group.

Experimental group
Fat content around the ovary Wet Weight (g) Fat weight per weight (%) Control Normal feed 0.067 ± 0.031 0.179 ± 0.086 High Fat Feed 0.829 ± 0.130 * 1.477 ± 0.167 * Metaformin 250 mg / kg 0.291 ± 0.093 *, # 0.660 ± 0.208 *, # RS administration group 500 mg / kg 0.187 ± 0.028 *, # 0.447 ± 0.075 *, # 250 mg / kg 0.278 ± 0.075 *, # 0.640 ± 0.188 *, # 125 mg / kg 0.521 ± 0.124 *, # 1.038 ± 0.276 *, # Statistical significance compared to normal feed * p <0.01;
Statistical significance # p <0.01 compared to high fat diet

Experimental Example  2. Determination of blood lipid content

2-1. Determination of total cholesterol in blood

About 1 ml of blood was collected from the abdominal vein under anesthesia on the last sacrifice day and centrifuged at 3000 rpm to separate serum from the experimental animal of Reference Example 1. Since then, the total cholesterol, triglycerides, LDL and HDL content in serum were measured using an automatic blood analyzer (AU400, olympus, Japan).

As a result, as shown in FIG. 1B, the change in the total cholesterol level in serum was significantly increased in the high fat feed control group compared to the normal feed control group. Could.

2-2. Determination of blood triglyceride content

As a result of measuring the content of the neutral lipid in the serum by the same method as Experimental Example 2-1, as shown in Figure 2, in the high-fat feed control group, the content of blood triglyceride increased significantly compared to the normal feed control group, The administration group was found to be significantly reduced compared to the high fat diet control group.

2-3. Determination of Low Density Lipid (LDL) and High Density Lipid (HDL) Levels in Blood

As a result of measuring the low-density lipoprotein and high-density lipoprotein content in serum by the same method as Experimental Example 2-1, as shown in FIG. 3, the LDL content in the serum was significantly increased in the high fat feeding control group compared to the normal feed control group. All the RS groups were significantly decreased compared to the high fat diet control group.

In addition, as shown in FIG. 4, the HDL content in the serum was significantly decreased in the high fat feed control group compared to the normal feed control group, but it was confirmed that the RS was significantly increased in all the administration groups.

Experimental Example 3 Determination of Leptin and Adiponectin in Blood

3-1. Determination of Leptin Content in Blood

Blood was collected from the abdominal vein under anesthesia on the final sacrifice day and centrifuged at 3000 rpm to separate serum. Blood leptin content in experimental animals was determined by Sahai et al. (Sahai A, et. al . , Am . J. Physiol . Gastrointest. Liver Physiol. , 287 , pp. G1035-43, 2004), using a radioimmunoassay kit (radioimmunoassay kit, Linco Research, MO, USA).

As a result, as shown in Figure 5, the high-fat feeding control group showed a significant increase in blood leptin content compared to the normal feed control group, it was confirmed that all the RS administration significantly reduced compared to the high-fat feeding control group.

3-2, Determination of the content of adiponectin in the blood

Blood was collected from the abdominal vein under anesthesia on the last sacrificial day and centrifuged at 3000 rpm to separate serum. The content of adiponectin in the blood of experimental animals was measured using an ELISA kit (Otsukapharm, Japan).

As a result, as shown in FIG. 6, the adiponectin content was significantly increased in the high fat feed control group compared to the normal feed control group, but it was confirmed that the RS was significantly decreased in the high fat feed control group.

Experimental Example 4 Histopathological Change

Observing Histopathological Changes The periovarian fat and the adipose tissue attached to the abdominal wall of the experimental animal of Reference Example 1 were removed, embedded, and then sections of 3 to 4 μm were prepared, and hematoxylin-eosin ( Hematoxylin-Eosin) staining was observed using an optical microscope. Average diameters of peri-ovarian fat and abdominal wall fat cells were calculated using an automatic image analyzer (DMI-300, Image Processing, DMI, Korea).

As shown in FIG. 7, the mean diameter change of the ovarian adipocytes was significantly increased in the ovarian adipocyte diameter in the high fat feed control group compared to the normal feed control group. It was confirmed that the decrease.

In addition, as shown in Figure 8, the thickness change of the accumulated abdominal wall fat was significantly increased in the abdominal wall fat thickness in the high-fat feed control group compared to the normal feed control, it was confirmed that significantly reduced compared to the high-fat feed supply control group in all RS Could.

As shown in FIG. 9, the mean diameter change of abdominal wall adipocytes was found to be significantly increased in abdominal wall adipocyte diameter in the high fat feed control group compared to the normal feed control group, and significantly decreased in all RS groups compared to the high fat feed supply control group. I could confirm it.

As shown in FIG. 10, histologic findings of the ovarian fat of the normal feed control group (a), the high fat feed control group (b), and the metformin 250 mg / kg administration group (c) were significant in the high fat feed supply control group. Hypertrophy was observed, but significantly decreased in the metformin-administered group, and as shown in FIG. 11, histologic findings of peri-ovarian fat of RS 500 (a), 250 (b) and 125 mg / kg-administered group (c) were high fat. It was observed that adipocyte hypertrophy caused by feeding was inhibited concentration-dependently by RS administration.

In addition, as shown in Figure 12 histological findings of abdominal wall fat of the normal feed control (a), high-fat feeding control (b) and metformin-administered group (c) in the high-fat feeding control, the fat cells remarkably similar to the surrounding ovary fat Hypertrophy was observed, but significantly decreased in metformin-treated group, and as shown in FIG. 13, histological findings of abdominal wall fat in RS 500 (a), 250 (b) and 125 mg / kg-administered group (c) showed high fat feed supply. It was observed that adipocyte hypertrophy caused by concentration was inhibited concentration-dependently by RS administration.

Examples of the formulation of the composition comprising the extract of the present invention will be described, but the present invention is not intended to limit it, but is intended to explain in detail only.

Formulation example  One. Powder  pharmacy

RS 20 mg

Lactose 100 mg

Talc 10 mg

The above ingredients are mixed and filled in an airtight cloth to prepare a powder.

Formulation example  2. Preparation of Tablets

RS 10 mg

Corn starch 100 mg

Lactose 100 mg

2 mg magnesium stearate

After mixing the above components, tablets are usually prepared by tableting according to the method for preparing tablets.

Formulation example  3. Manufacture of capsule

RS 10 mg

3 mg of crystalline cellulose

Lactose 14.8 mg

Magnesium Stearate 0.2 mg

According to a conventional capsule preparation method, the above ingredients are mixed and filled into gelatin capsules to prepare capsules.

Formulation example  4. Preparation of injections

RS 10 mg

Mannitol 180 mg

Sterile distilled water for injection 2974 mg

_{Na 2 HPO 4 · 12H 2 O} 26 mg

It is usually prepared in the above ingredient content per ampoules (2 ml) according to the preparation method of the injection.

Formulation example  5. Liquid  Produce

RS 20 mg

10 g of isomerized sugar

5 g of mannitol

Purified Water Proper Amount

Normally, each component is added to the purified water to dissolve according to the preparation method of the liquid solution, lemon flavor is added, the above ingredients are mixed, purified water is added, the whole is adjusted to 100 ml by the addition of purified water, and then filled into a brown bottle and sterilized. To prepare a liquid solution.

Formulation example  6. Preparation of dietary supplements

RS 1000 mg

Vitamin mixture proper amount

70 μg of Vitamin A Acetate

Vitamin E 1.0 mg

Vitamin B1 0.13 mg

Vitamin B2 0.15 mg

Vitamin B6 0.5 mg

0.2 μg of vitamin B12

Vitamin C 10 mg

10 μg biotin

Nicotinamide 1.7 mg

50 μg folic acid

Calcium Pantothenate 0.5 mg

Mineral mixture

Ferrous Sulfate 1.75 mg

Zinc Oxide 0.82 mg

Magnesium carbonate 25.3 mg

15 mg potassium monophosphate

Dicalcium Phosphate 55 mg

Potassium Citrate 90 mg

Calcium Carbonate 100 mg

Magnesium chloride 24.8 mg

Although the composition ratio of the above-mentioned vitamin and mineral mixtures is a composition that is relatively suitable for the health functional food, the composition is mixed in a preferred embodiment, but the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional health functional food manufacturing method. Then, the granules may be prepared and used for preparing the nutraceutical composition according to a conventional method.

Formulation example  7. Manufacture of health drinks

RS 1000 mg

Citric acid 1000 mg

100 g oligosaccharides

Plum concentrate 2 g

1 g of taurine

900 ml of purified water whole

After mixing the above components according to the conventional healthy beverage production method, and stirred and heated at 85 ℃ for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2 L container, sealed sterilization and then refrigerated and stored Used to prepare the healthy beverage composition of the invention.

Although the composition ratio is a mixture of the components suitable for the preferred beverage as a preferred embodiment, the blending ratio may be arbitrarily varied according to the regional and national preferences such as the demand level, the demanding country, and the intended use.

1 is a view showing the change in weight (A), the change in total cholesterol level in serum (B) during the experiment,

Figure 2 is a diagram showing the change in the content of triglyceride in serum,

Figure 3 is a view showing the change in serum LDL content,

4 is a diagram showing a change in HLD content in serum,

5 is a diagram showing the change in leptin content in serum,

6 is a diagram showing a change in adiponectin content in serum,

7 is a view showing the change in the average diameter of the ovarian fat cells,

8 is a view showing the thickness change of the accumulated abdominal wall fat,

9 is a diagram showing the change in the mean diameter of abdominal wall fat cells,

10 is a diagram showing the histological changes of the ovarian fat of the normal feed control (a), high fat feed supply control (b) and metformin administration group (c),

11 is a diagram showing the histological changes of the ovarian fat in the RS 500 (a), 250 (b), 125 mg / kg administration group (c),

12 is a diagram showing the histological changes of abdominal wall fat of the normal feed control (a), high fat feed supply control (b) and metformin administration group (c),

Figure 13 shows the histological changes of abdominal wall fat in RS 500 (a), 250 (b), 125 mg / kg administration group (c).

Claims (6)

A pharmaceutical composition for the prevention and treatment of hyperlipidemia or obesity, containing water extract of moths as an active ingredient. delete delete delete Health functional food for the prevention and improvement of hyperlipidemia or obesity containing water extract of moth as an active ingredient. delete

Images